No statistically significant difference was found in the AUC of sFlt‐1/PlGF ratio and plasma PROK1 in the PE‐EC/CH with PE group and total HDP patient cohort (both p >0.05, 0.813 vs. 0.778, 0.759 vs. 0.751); however, sFlt‐1/PlGF ratio in combination with plasma PROK1 improved the diagnosis of adverse pregnancy outcomes in the PE‐EC/CH with PE group and the total HDP cohort, respectively, as a separate metric (both p <0.05, 0.860 vs. 0.813 and 0.778, 0.817 vs. 0.759 and 0.751). Here, PROK1 is linked to cyclic hematopoiesis.